How is amblyopia treated?

Weakness of vision, or amblyopia, is a neurodevelopmental disorder characterized by reduced visual acuity in one or both eyes despite the absence of any detectable structural abnormality in the eye or optic pathway. It arises during early childhood—typically before age 7—when abnormal visual experience disrupts normal maturation of the visual cortex. Common causes include strabismus (misalignment of the eyes), anisometropia (a significant difference in refractive error between the two eyes), and stimulus deprivation (e.g., due to congenital cataract or ptosis).

Treatment must begin as early as possible—ideally before age 5—to maximize neural plasticity and visual recovery. The cornerstone of therapy is correcting any underlying refractive error with accurate, full-time spectacle correction. Once refractive correction is optimized and stable for at least several weeks, occlusion therapy (patching the stronger eye) is initiated to force use of the amblyopic eye. Patching regimens are individualized: for moderate amblyopia, 2 hours per day is often effective; for severe cases, up to 6 hours daily may be prescribed. Alternatively, pharmacologic penalization using atropine 1% drops in the dominant eye (typically once weekly) may be used, especially when patching adherence is poor.

Recent evidence supports the inclusion of perceptual learning activities—such as computer-based visual tasks requiring contrast discrimination, motion detection, or contour integration—as adjunctive therapy, particularly in older children or those with residual amblyopia after conventional treatment. Importantly, treatment requires consistent monitoring every 4–8 weeks to assess visual acuity improvement, adjust patching duration, and reassess refractive status. While outcomes are generally excellent in young children treated promptly, residual deficits may persist if diagnosis or intervention is delayed beyond age 7–10 years.